Trevena

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days and, as a result of regaining compliance, its common stock will continue to be listed on the Nasdaq Capital Market.

Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones

Trevena, Inc. (NASDAQ:TRVN ) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Operator Hello and welcome to Trevena, Inc. First Quarter 2023 Earnings Call.

Trevena, Inc. (TRVN) Q1 2023 Earnings Call Transcript

OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company's China partner Jiangsu Nhwa Pharmaceutical

Trevena Reports First Quarter 2023 Results and Provides Business Update

Apple

Airbnb

Akamai Technologies

AMC Entertainment

Anheuser-Busch InBev

Blackstone Group

Colgate-Palmolive

Credit Suisse

Duolingo

GameStop

Hain Celestial Group

Harmonic

Lucid Group

Mullen Automotive

Novavax

PacWest Bancorp

Palantir Technologies

Plug Power

PayPal

Rivian Automotive

Shoals Technologies Group

iShares 0-5 Year TIPS Bond ETF

Skyworks Solutions

Tempur Sealy International

Friday's bullish session on Wall Street seems to have gone nowhere, save for the Nasdaq Composite COMP wriggling its way out of a bear market.

‘It's ridiculous.' Buy short-term Treasury bills because debt-ceiling deal will come, says bond legend Bill Gross

CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023.

Trevena to Release First Quarter 2023 Financial Results on May 15, 2023

Crown ElectroKinetics

Ideanomics Inc

Use these tips to make money when momentum trading penny stocks The post Momentum Trading With Penny Stocks: Quick Guide  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Momentum Trading With Penny Stocks: Quick Guide

Shares of Trevena Inc. TRVN exploded more than five-fold higher — up 420.6% — on very active trading Monday, after the Pennsylvania-based biopharmaceutical company said its China-based partner Jiangsu Nhwa received formal approval from China health regulators for the pain treatment Olinvyk. The stock, which had been halted 21 times for volatility since the open, has seen 75.7 million shares change hands, compared with the full-day average over the past 30 days of about 111,100 shares.

Trevena stock soars toward 5-fold gain in very active trading, after pain treatment gets approved in China

Ginkgo Bioworks Holdings

Grab Holdings Ltd

Invitae

Are these the best penny stocks to buy right now? Here's what's moving on Monday.

Best Penny Stocks To Buy Now? 4 To Watch Before May CPI Data

Trevena (NASDAQ: TRVN ) stock is rocketing higher on Monday after Chinese partner Jiangsu Nhwa got approval for one of its treatments. The National Medical Products Administration granted approval to Jiangsu Nhwa for Trevena's OLINVYK.

Why Is Trevena (TRVN) Stock Up 165% Today?

Trevena's partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15 million to Trevena expected on first commercial sale in China, based on ex-US Royalty-Based Financing with R-Bridge Healthcare Fund, an affiliate of CBC Group CHESTERBROOK, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that its partner in China, Jiangsu Nhwa, received formal approval from the National Medical Products Administration for OLINVYK.

Trevena Announces Approval of OLINVYK in China

CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that members of Management will participate in three upcoming conferences.

Trevena to Participate in Three Upcoming Conferences

Trevena, Inc. (NASDAQ:TRVN ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Jason Butler - JMP Securities Brandon Folkes - Cantor Fitzgerald Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Trevena Fourth Quarter and Full Year 2022 Earnings Call.

Trevena, Inc. (TRVN) Q4 2022 Earnings Call Transcript

OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of ARTEMIS patients at Wake Forest Baptist Health

Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study

Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study

Trevena Reports Fourth Quarter 2022 Results and Provides Business Update

Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET

Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.

Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate

New study complements the ongoing proof-of-concept study, and will provide further insight into TRV045 target engagement and mechanism of action for the potential treatment of epilepsy and other CNS disorders New study complements the ongoing proof-of-concept study, and will provide further insight into TRV045 target engagement and mechanism of action for the potential treatment of epilepsy and other CNS disorders

Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders

OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects

Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY

New Phase 1 clinical study designed to build on nonclinical evidence of anti-inflammatory signaling and potential disease-modifying effect of TRV045 in the treatment of epilepsy and other CNS disorders

Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting

Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings

CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days and, as a result of regaining compliance, its common stock will continue to be listed on the Nasdaq Capital Market.

Trevena Regains Compliance with Nasdaq Listing Requirements

CHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,614,380 shares of common stock and warrants to purchase up to an aggregate of 2,614,380 shares of common stock, at a combined offering price of $3.06 per share of common stock (or pre-funded warrants in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $2.95 per share, will be exercisable immediately upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about November 18, 2022, subject to the satisfaction of customary closing conditions.

Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Trevena, Inc. (NASDAQ:TRVN ) Q3 2022 Results Earnings Conference Call November 13, 2022 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Douglas Tsao - H.C. Wainwright & Co. Jason Butler - JMP Securities Brandon Folkes - Cantor Fitzgerald Jeff Jones - Oppenheimer & Co. Inc. Operator Greetings and welcome to Trevena Inc. Third Quarter 2022 Earnings Conference Call.

Trevena, Inc. (TRVN) Q3 2022 Results - Earnings Call Transcript

CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 5:01 p.m. ET on Wednesday, November 9, 2022. Trevena's common stock will continue to be traded on the Nasdaq Capital Market under the symbol TRVN and will begin trading on a split-adjusted basis when the market opens on Thursday, November 10, 2022. The reverse stock split is intended to enable Trevena to regain compliance with the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market. The new CUSIP number for Trevena's common stock following the reverse stock split will be 89532E 208.

Trevena Announces Reverse Stock Split

Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates

News for Trevena Stock (TRVN)